In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Develop A Patient-First Strategy For CGT Commercialization

A patient centric approach to a complex treatment journey

Executive Summary

Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.

You may also be interested in...



The Power Of AI To Map The Patient Journey

Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.

Parkinson’s Disease: Ripe For A Rethink

Despite decades of R&D, there are no disease modifying therapies on the market for Parkinson’s disease, and few efficacious products for non-motor symptoms. Clinical setbacks have been rife but breakthroughs in diagnostics and a better understanding of disease pathology brings hope for the future. In Vivo speaks to some of those responsible for bringing innovation to the field. 

The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs

As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel